Introduction
============

Diabetic ketoacidosis (DKA) is a serious medical emergency resulting from relative or absolute insulin deficiency and the unopposed action of counter-regulatory hormones, such as glucagon, cortisol, and catecholamines \[[@B1]\]. The hepatic metabolism of free fatty acids generates ketoanions, such as beta-hydroxybutyrate and acetoacetate \[[@B2],[@B3]\]. Impaired tissue perfusion due to volume contraction and the adrenergic response to the often severe underlying precipitating illness result in lactate production \[[@B4]\]. Acute kidney injury leads to accumulation of other unmeasured anions, such as sulphate, urate, and phosphate \[[@B5]\]. All these, together with hyperchloremia which predominates during the recovery phase of DKA \[[@B6]\], contribute to the development of acidemia, which often is severe \[[@B7],[@B8]\].

Experimental studies suggest that metabolic acidemia can impair myocardial contractility, reduce cardiac output, affect oxyhemoglobin dissociation and tissue oxygen delivery, inhibit intracellular enzymes, such as phosphofructokinase, alter cellular metabolism, and result in vital organ dysfunction \[[@B9]-[@B12]\]. Thus, the target of therapy in DKA has historically placed importance on the rapid reversal of acidemia, in addition to the correction of dehydration and insulin deficiency.

As a result of the physiological paradigm, correction of severe acute acidemia with intravenous bicarbonate to attenuate the deleterious effects continues to be utilized by some practitioners. This approach has received wide acceptance in the past, but based on currently available evidence, and concerns about the potential adverse effects in children and adults, the administration of bicarbonate in DKA requires re-examination.

The objective of this systemic review was to examine the medical evidence to date, on the administration of bicarbonate versus no bicarbonate, in the emergent treatment of severe acidemia in pediatric and adult patients with DKA, with regards to the physiological and clinical efficacies and harms of this intervention.

Methods
=======

Information source
------------------

Literature search was performed using the PUBMED database. The list of potentially relevant article titles and abstracts was generated by using the keywords, \"bicarbonate\" AND \"diabetic ketoacidosis.\"

Study selection and eligibility criteria
----------------------------------------

Two investigators (HC and AS) independently reviewed the article titles and abstracts. The following exclusion criteria were first applied: 1) review articles; 2) commentaries, letters, or editorials; 3) non-English articles; 4) animal studies; 5) all articles not related to acid-base issues, bicarbonate use, or cerebral edema in DKA; 6) publications before 1960.

The remaining papers were deemed relevant if they fulfilled the following inclusion criteria:

1\. Population: Both adult and pediatric populations with diagnosis of DKA

2\. Intervention: Intravenous sodium bicarbonate therapy

3\. Comparator: Bicarbonate administration versus no bicarbonate for the emergent treatment of diabetic ketoacidosis

4\. Outcome: Primary outcomes are the difference in mortality and duration of hospitalization. Secondary outcome is a combination of various physiological and clinical outcomes. Physiological outcomes include resolution of acidosis and ketosis, insulin sensitivity and glycemic control, potassium balance, tissue oxygenation, and cerebrospinal fluid (CSF) acidosis. Clinical outcomes include hemodynamic stability and neurological outcomes, including that of cerebral edema (CE)

5\. Study type: All trials, including randomized and nonrandomized case-control studies, as well as case reports and series were selected.

Two investigators (HC and AS) reviewed all remaining papers in entirety after the application of the above-mentioned criteria. A third independent investigator (RB) adjudicated any disagreements regarding paper inclusion.

Results
=======

Search results
--------------

The systematic search identified 508 potentially relevant citations. Following application of the inclusion and exclusion criteria, 44 articles were eventually selected and the full manuscripts were reviewed. The selection process is illustrated in Figure [1](#F1){ref-type="fig"}.

![**Overview of study selection process**.](2110-5820-1-23-1){#F1}

Study characteristics
---------------------

Twelve publications were case-controlled studies on bicarbonate administration versus no bicarbonate in DKA. Of these, two studies were nonblinded randomized controlled trials (RCT) \[[@B13],[@B14]\], and one study was a double-blind RCT \[[@B15]\]. A total of 73 adult patients were included in these three RCTs. The remaining nine studies were nonrandomized, prospective, or retrospective studies, which include six adult studies \[[@B16]-[@B21]\], two involving both adult and pediatric patients \[[@B22],[@B23]\], and one pediatric study \[[@B24]\]. No RCTs have been performed in the pediatric cohort, and no trials have examined bicarbonate treatment in DKA patients with an admission pH \< 6.85. In addition, four pediatric nonrandomized prospective and retrospective studies investigated the association between bicarbonate administration in DKA and risk of CE \[[@B25]-[@B28]\]. There were no similar studies in the adult DKA cohort.

Study threshold for and dose of bicarbonate
-------------------------------------------

In Table [1](#T1){ref-type="table"} we summarized the threshold for bicarbonate administration in various studies, which includes the initial degree of acidemia and base deficit \[[@B4],[@B13]-[@B24],[@B29]-[@B36]\]. There is heterogeneity of initial pH threshold for bicarbonate therapy, which has become more stringent over the years, from pH \< 7.20 in the past to pH \< 7.00.

###### 

Degree of baseline acidemia and base deficit in DKA patients with bicarbonate administered

  Reference                    Population      Nature of study     Mean initial blood indices                        
  ---------------------------- --------------- ------------------- ---------------------------- -------------------- ------------
  Addis 1964 \[[@B29]\]        A. (N = 3)      Case series         6.94                         Mostly unavailable   
  Kuzemko 1969 \[[@B30]\]      P. (N = 6)      Case series         7.05                         23                   8.0
  Zimmet 1970 \[[@B4]\]        A. (N = 11)     Case series         7.09                         24                   4.4
  Soler 1972 \[[@B22]\]        A+P. (N = 18)   Prospective C-C     \< 7.2                       NR                   \< 10.0
  Krumlik 1973 \[[@B31]\]      P. (N = 27)     Case series         7.05                         NR                   7.6
  Soler 1974 \[[@B32]\]        A. (N = 1)      Case report         6.85                         NR                   6.0
  Munk 1974 \[[@B16]\]         P. (N = 5)      Prospective C-C     7.05                         22                   8.7
  Assal 1974 \[[@B23]\]        A+P. (N = 9)    Retrospective C-C   7.06                         NR                   5.6
  Keller 1975 \[[@B33]\]       A. (N = 58)\*   Case series         \< 7.2                       NR                   NR
  Reddy 1977 \[[@B34]\]        P. (N = 19)     Case series         7.07                         NR                   6.5
  Lutterman 1979 \[[@B17]\]    A. (N = 12)     Retrospective C-C   6.89                         NR                   NR
  Lever 1983 \[[@B18]\]        A. (N = 52)     Retrospective C-C   6.94-7.00^†^                 NR                   3.4-4.3^†^
  Hale 1984 \[[@B13]\]         A. (N = 16)     RCT                 6.85                         NR                   7.0
  Morris 1986 \[[@B14]\]^‡^    A. (N = 10)     RCT                 7.03                         NR                   3.6
  Gamba 1991 \[[@B15]\]^‡^     A. (N = 9)      RCT (DB)            7.05                         NR                   2.9
  Okuda 1996 \[[@B19]\]        A. (N = 3)      Prospective C-C     6.98                         NR                   2.0
  Green 1998 \[[@B24]\]        P. (N = 57)     Retrospective C-C   7.02                         40                   NR
  Viallon 1999 \[[@B20]\]      A. (N = 24)     Retrospective C-C   6.93                         NR                   3.1
  Latif 2002 \[[@B21]\]        A. (N = 4)      Retrospective C-C   6.85                         NR                   NR
  Kamarzaman 2009 \[[@B35]\]   A. (N = 1)      Case report         6.27                         41                   4.0
  Guneysel 2009 \[[@B36]\]     A. (N = 1)      Case report         6.82                         27                   8.4

A = adults; P = pediatrics; N = number of patients who received bicarbonate, if breakdown available; C-C = case-control; RCT = randomized, controlled trial; DB = double-blinded; Bicarb = bicarbonate level; NR = not reported

\*Breakdown of patients with or without bicarbonate administered not provided

^†^Mean values provided separately for two different study centers

^‡^Patients with initial pH \< 6.9 were excluded from the RCT

Dosing methods vary widely with study design and physician preference, and these are summarized in Table [2](#T2){ref-type="table"}. Concentrated bicarbonate dosing based on calculations using predictive formulas incorporating base deficit \[[@B37],[@B38]\] results in a tendency for over-correction and alkalosis \[[@B29],[@B30]\]. Aiming for a more modest and intermediate pH target with bicarbonate dose less than half of that predicted, or dose titrated based on pH severity, were some of the variable approaches adopted subsequently by investigators \[[@B4],[@B23]\]. Consequentially, the average bicarbonate dose reported in studies appears to have decreased over the years to an overall amount of 120-150 mmol for adults and 2 mmol/kg for children.

###### 

Summary of bicarbonate dose administered in case series and studies

  Reference                    Nature of Study   Dose of bicarbonate given (mean)   Dose Estimation                  Timing (range)                                             
  ---------------------------- ----------------- ---------------------------------- -------------------------------- -------------------------- ------------------------------- -------------------------
  Addis 1964 \[[@B29]\]        CS                8.4                                413                              NR                         based on calculated dose        150 initial, and rest
                                                                                                                                                                                over 1.5 to 12 hr
  Kuzemko 1969 \[[@B30]\]^P^   CS                8.4                                255                              NR                         based on calculated dose        over 3 to 32 hr
  Zimmet 1970 \[[@B4]\]        CS                NR                                 185                              NR                         based on pH severity            within initial 4 hr
                                                                                                                                                (≈ half of calculated dose)     
  Soler 1972 \[[@B22]\]^AP^    PrC               1.0                                200 - 400^†^                     NR                         NR                              NR
  Krumlik 1973 \[[@B31]\]^P^   CS                7.5                                115 (3.3/kg) to reach pH ≥ 7.2   based on calculated dose   half over 30 min,               
                                                                                    144 (3.9/kg) to reach pH ≥ 7.3                              rest over 2 hrs                 
  Munk 1974 \[[@B16]\]^P^      PrC               NR                                 130                              2.44                       NR                              NR
  Assal 1974 \[[@B23]\]^AP^    ReC               NR                                 230                              NR                         half of calculated dose given   within initial 4 hr
  Keller 1975 \[[@B33]\]       CS                NR                                 345                              NR                         based on calculated dose        within initial 24 hr
  Reddy 1977 \[[@B34]\]^P^     CS                ≈ 0.6                              NR                               2.50                       slow infusion till pH \> 7.2    over mean of 4.9 hr
  Lutterman 1979 \[[@B17]\]    ReC               1.4                                167                              NR                         standard dose for all           within initial 6 hr
  Lever 1983 \[[@B18]\]        ReC               NR                                 130-135^╫^                       NR                         NR                              majority slow infusion
  Hale 1984 \[[@B13]\]         RCT               1.3                                150                              NR                         standard dose for all           over 1 hr
  Morris 1986 \[[@B14]\]       RCT               NR                                 120                              NR                         titrated to pH, repeated till   intermittent dose, over
                                                                                                                                                pH \> 7.15                      30 min; 2 hr interval
  Gamba 1991 \[[@B15]\]        RCT (DB)          ≈ 7.5                              84                               NR                         titrated to pH, repeated till   intermittent dose, over
                                                                                                                                                pH rise \> 0.05                 30 min; 2 hr interval
  Okuda 1996 \[[@B19]\]        PrC               NR                                 200                              NR                         standard dose (50 mmol/hr)      over 4 hr
  Green 1998 \[[@B24]\]^P^     ReC               NR                                 NR                               2.08                       NR                              NR
  Viallon 1999 \[[@B20]\]      ReC               1.4                                120                              NR                         as per attending physician      over 1 hr
  Latif 2002 \[[@B21]\]        ReC               NR                                 50                               NR                         standard dose for all           NR

CS = case series; PrC = prospective case-control; ReC = retrospective case-control; RCT = randomized controlled trial; DB = double-blind; Conc = concentration; NR = not reported; mM = mmol; Wt-adj = weight-adjusted

^†^Mean values provided separately for two study arms; ^╫^mean values provided separately for two study centers

^P^Pediatric studies; ^AP^mainly adults but including pediatric patients

Slow infusions using half-isotonic or isotonic preparations (approximately 1%) or small intermittent boluses of more concentrated preparations (approximately 8.4%) were preferentially used in later studies \[[@B13]-[@B15],[@B17],[@B18],[@B20]\] to avoid too rapid pH or osmolality changes, with no evidence of risk or benefit with either methods.

Primary outcomes
----------------

### Duration of hospitalization

One single-center retrospective pediatric study assessed duration of hospitalization as an outcome measure \[[@B24]\]. Duration of hospitalization was significantly longer (87 vs. 67 hours, *p*= 0.01) for the bicarbonate group vs. children treated without bicarbonate. However, there was no adjustment for confounding variables. With multivariate analysis, duration of hospitalization was 23% longer in the bicarbonate group but did not reach statistical significance (*p*= 0.07). Using 29 pairs of matched patients (for calendar year, pH, and creatinine), duration of hospitalization was 37% longer in the bicarbonate group (*p*= 0.011).

In another brief report of 41 patients admitted for severe DKA, 5 patients had pH \< 7.0 (mean 6.85 ± 0.09); only 4 received a small 50-mmol bolus of sodium bicarbonate, whereas 36 patients with pH \> 7.0 (mean 7.15 ± 0.11) did not \[[@B21]\]. Bicarbonate therapy did not seem to have an impact on duration of hospitalization. Therefore, there may be a weak association with prolonged hospitalization in children with DKA treated with additional bicarbonate therapy, but the evidence is of very poor quality.

### Mortality outcome

No published trials on the use of bicarbonate therapy in DKA were able to comment on any mortality difference with or without its use. Critically ill DKA cases with severe metabolic acidemia were excluded from most studies.

Secondary outcomes (physiological)
----------------------------------

### Resolution of acidosis

Eight case-control studies have examined the rates of acidosis reversal with or without additional bicarbonate therapy, including three RCTs. The results are summarized in Table [3](#T3){ref-type="table"}. Improvements in pH and serum bicarbonate levels were used as markers of acidosis reversal \[[@B13]-[@B15],[@B17]-[@B20],[@B24]\].

###### 

Key studies on resolution of acidosis and ketosis with bicarbonate therapy in DKA

  References                       Trial design      No. of patients (bicarb vs. control)   Mean age (yr) and initial pH   Bicarbonate infusion                      Control                                                   Acidosis and ketosis
  -------------------------------- ----------------- -------------------------------------- ------------------------------ ----------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------
  Hale et al. \[[@B13]\]           RCT               16 vs. 16                              47 vs. 41                      (1^st^hr: 1 L isotonic saline for all)    Higher pH and bicarb levels at 2 hr                       
  *Br Med J 1984*                  (single center)                                          6.85 vs. 6.85                  2^nd^hr: 1 L isotonic bicarb vs.          1 L isotonic saline                                       in bicarb arm vs. control, *p*\< 0.01
                                                                                                                                                                                                                               BUT
                                                                                                                           (3^rd^hr: 1 L isotonic saline for all)    Slower decline in blood ketone in 1st hr in bicarb arm    
                                                                                                                                                                                                                               
  Morris et al. \[[@B14]\]         RCT               10 vs.11                               34 vs. 28                      133.8 mmol if pH 6.9-6.99                 no alkali                                                 No difference in rate of change of pH, bicarb, ketones
  *Ann Intern Med*1986             (single center)                                                                         OR 89.2 mmol if pH 7.0-7.09                                                                         OR time to reach pH 7.3
                                                                                            7.03 vs. 7.00                  OR 44.6 mmol if pH 7.1-7.14                                                                         OR bicarb levels to reach 15 mmol/L
                                                                                                                           (over 30 min, 2 hourly until pH ≥ 7.15)                                                             
                                                                                                                                                                                                                               
  Gamba et al. \[[@B15]\]          RCT               9 vs. 11                               29 vs. 28                      133.5 mmol/150 ml (pH 6.9-6.99)           0.9% saline, also                                         Higher pH at 2 hr in bicarb arm, *p*\< 0.02
  *Rev Inves Clin*1991             double-blind                                                                            89 mmol/100 ml (pH 7.0-7.09)              in similar aliquots                                       AND higher bicarb in bicarb arm, *p*\< 0.01
                                   (single center)                                          7.05 vs. 7.04                  44.8 mmol/50 ml (pH 7.1-7.14)                                                                       
                                                                                                                           (over 30 min, repeated at 2 hr                                                                      Change in pH and bicarb larger in bicarb arm at 2 hr,
                                                                                                                           if pH increase by \< 0.05)                                                                          *p*\< 0.01
                                                                                                                                                                                                                               
  Okuda et al. \[[@B19]\]          Prospective       3 vs. 4                                24 vs. 34                      50 mmol/hr over 4 hr                      No alkali                                                 Paradoxical increase in plasma acetoacetate in 1^st^3 hr
  *J Clin Endocrinol Metab 1996*   nonrandomized                                                                                                                                                                               in bicarb arm vs. control
                                   nonblinded                                               6.98 vs. 7.27                  (IV insulin 0.1 U/kg/hr + 0.9% saline)    Increase in plasma 3-hydroxybutyrate level after bicarb   
                                   (single center)                                          (*p*\< 0.05)                                                                                                                       ceased vs. steady decline throughout in control
  Lutterman et al. \[[@B17]\]      Retrospective     12 vs. 12                              41 vs. 34                      167 mmol/L in 1 L                         Low-dose insulin                                          No difference in mean pH rise in 1^st^2 hr
  *Diabetologia*1979               (single center)                                                                         over 1 hr (if pH ≤ 7.0)                   IV 8 U/hr                                                 OR mean time to reach pH ≥ 7.30
                                                                                            6.89                           (with high dose insulin                                                                             OR rate of decline of ketosis
                                                                                                                           mean 260 U in 1st 6 hrs)                                                                            
                                                                                                                                                                                                                               
  Lever et al. \[[@B18]\]          Retrospective     52 (73 cases)                          22.5-37.4 vs.                  mean 130-135 mmol                         No alkali                                                 No difference in mean change in bicarb level per hr
  *Am J Med*1983                   (2 centers)       vs                                     24.5-48.0                      (majority slow infusion)                                                                            OR mean change in pH per hr
                                                     21 (22 cases)                          6.94-7.00 vs.                                                                                                                      
                                                                                            6.89-7.07                                                                                                                          
                                                                                                                                                                                                                               
  Viallon et al. \[[@B20]\]        Retrospective     24 vs. 15                              45 vs. 47                      mean 120 mmol (88-166)                    No alkali                                                 No difference in variation of mean pH, bicarb level, AG
  *Crit Care Med*1999              (single center)                                                                         1.4% over 1 hr infusion                                                                             anion gap in 1st 24 hr
                                                                                            6.93 vs. 7.00                                                                                                                      OR mean time to reach pH \> 7.30
                                                                                                                                                                     OR urine ketone clearance                                 
                                                                                                                                                                                                                               
  Green et al\[[@B24]\]            Retrospective     57 (90 cases)                          9.6 vs. 10.1                   mean 2.08 mmol/kg (0.53-                  No alkali                                                 Unadjusted rate of bicarb rise faster in bicarb arm at
  *Ann Emerg Med*1998              (single center)   vs                                                                    7.37 mmol/kg)                                                                                       24 hr, *p*= 0.033
  (pediatric)                                        49 (57 cases)                          7.02 vs. 7.06                                                                                                                      No difference in bicarb rise at 12 and 24 hr, or time to reach
                                                                                                                                                                                                                               bicarb of 20 mmol/L (matched pair and multivariate analysis)

cases: DKA episodes; IV: intravenous; hr: hour; min: minutes; bicarb: bicarbonate

Two adult RCTs demonstrated biochemical benefit in terms of acidosis reversal time, with improved pH and bicarbonate levels at 2 hours of therapy in the bicarbonate arm. Of these, one study administered isotonic bicarbonate as a slow infusion \[[@B13]\], whereas the other administered small intermittent bicarbonate boluses of higher concentration titrated to severity of pH \[[@B15]\]. The latter study extended the follow-up duration to 24 hours of therapy and did not find a sustained biochemical benefit beyond 2 hours. A third adult RCT administered similar incremental small boluses of sodium bicarbonate but did not establish a similar biochemical advantage \[[@B14]\]. In addition, three retrospective adult studies \[[@B17],[@B18],[@B20]\] and one retrospective pediatric study \[[@B24]\] showed no improvement in acidosis resolution with use of bicarbonate therapy.

### Resolution of ketosis

As shown in Table [3](#T3){ref-type="table"} two adult studies showed paradoxical worsening of ketonemia, including a slower decline in ketonemia in the first hour of bicarbonate infusion in a RCT \[[@B13]\], and an increase in plasma acetoacetate levels during the initial three hours of bicarbonate infusion in a small, prospective, nonrandomized study \[[@B19]\].

### Insulin sensitivity and glycemic control

Results of pediatric and adult studies that reported insulin sensitivity and glycemic control as outcome measures are summarized in Table [4](#T4){ref-type="table"}. No significant difference in rate of glucose decline or insulin requirement was demonstrated with bicarbonate treatment.

###### 

Studies on insulin sensitivity and glycemic control

  Reference                     Trial design and size   Bicarb dose (intervention)   Insulin dose                  Glycemic control
  ----------------------------- ----------------------- ---------------------------- ----------------------------- -----------------------------------------------------------
  Hale et al. \[[@B13]\]        RCT                     150 mmol                     IM 20 U in 1st hr,            No difference in glucose decline over 2 hr
  *Br Med J*1984                Adults (N = 32)         (standard)                   6 U in both 2nd and 3rd hr    
                                                                                                                   
  Morris et al. \[[@B14]\]      RCT                     120.4 mmol                   Insulin 0.3 U/kg (IV + IM),   No difference in time for glucose to reach 250 mg/dL
  *Ann Intern M*1986            Adults (N = 21)         (mean)                       then IM 7 U/hr                No difference in total insulin required
                                                                                                                   (1 hypoglycemia in control group)
                                                                                                                   
  Gamba et al. \[[@B15]\]       RCT                     84 mmol                      IV insulin 5 U/hr             No difference in glucose levels throughout 24 hrs
  *Rev Cl In*1991               Adults (N = 20)         (mean)                                                     No difference in total insulin required to reduce glucose
                                                                                                                   to \< 250 mg/dL, or till urine ketones were \< 2+
                                                                                                                   
  Lutterman et al. \[[@B17]\]   Retrospective           167 mmol                     High-dose insulin (mean       No difference in glucose decline in 1st 2 hrs
  *Diabetologia*1979            Adults (N = 24)         (standard)                   260 ± 60 U in 1st 6 hr)       No difference in mean glucose in 1st 8 hours
                                                                                     vs. low dose 8 U/hr           (4 hypoglycemia in bicarb arm)
                                                                                                                   
  Lever et al. \[[@B18]\]       Retrospective           130-135 mmol                 IM or IV insulin              No difference in glucose decline in 7 - 9 hrs
  *Am J Med*1983                Adult (N = 73)          (standard)                   5-6 U/hr (for all)            (2 hypoglycemia in bicarb arm)
                                                                                                                   
  Viallon et al. \[[@B20]\]     Retrospective           120 ± 40 mmol                IV insulin for all            No difference in normalization time of glycaemia
  *Crit Care Med*1999           Adult (N = 39)          (mean)                       (dose unspecified)            OR in mean quantity of insulin infused
                                                                                                                   
  Green et al. \[[@B24]\]       Retrospective           2.08 mmol/kg                 IV insulin for all            No difference in insulin requirement in 24 hrs
  *Ann Em Med*1998              Pediatrics (N = 106)    (mean)                       (dose unspecified)            
                                                                                                                   
  Okuda et al. \[[@B19]\]       Prospective             200 mmol                     IV 0.1 U/kg bolus insulin     No difference in glucose decline over 7 - 8 hrs
  *J Clin En M*1996             Adults (N = 7)          (standard)                   and then IV 0.1 U/kg/hr       

IM = intramuscular; IV = intravenous; U = units; bicarb = bicarbonate; L = liter; hr = hour

### Potassium balance

Seven studies examined potassium balance as an outcome measure and are summarized in Table [5](#T5){ref-type="table"}. One double-blind adult RCT, with mean bicarbonate dose of 84 ± 34 mmol, demonstrated lower serum potassium at 24 hours of therapy in the bicarbonate arm \[[@B15]\]. Another adult retrospective study, with mean bicarbonate dose of 120 ± 40 mmol, showed higher potassium supplementation in bicarbonate arm over 24 hours \[[@B20]\]. Four other studies (including one pediatric study) did not detect any statistical difference in the potassium balance \[[@B14],[@B17],[@B18],[@B24]\].

###### 

Studies on potassium balance and supplementation

  Reference                     Trial design and size   Bicarb dose (intervention)   Insulin dose                  Potassium balance and supplementation
  ----------------------------- ----------------------- ---------------------------- ----------------------------- -----------------------------------------------------------
  Morris et al. \[[@B14]\]      RCT                     120.4 mmol                   Insulin 0.3 U/kg (IV + IM),   No difference in serum K decline
  *Ann Intern Med*1986          Adults (N = 21)         (mean)                       then IM 7 U/hr                
                                                                                                                   
  Gamba et al. \[[@B15]\]       RCT                     84 mmol                      IV insulin 5 U/hr             Lower serum K at 24 hr for bicarb arm vs. control,
  *Rev Cl In*1991               Adults (N = 20)         (mean)                                                     *p*\< 0.05
                                                                                                                   BUT trend for more K given in control
                                                                                                                   
  Soler et al. \[[@B22]\]       Prospective             Grp 1: none                  Grp 1: 234 U/24 hr            More K requirement over 24 hr for Grp 3
  *Lancet*1972                  Mixed (N = 25)          Grp 2: 200 mmol              Grp 2: 287 U/24 hr            Estimated 30 mmol/L of K needed for Grps 1 & 2,
  (3-arm study; age 13-84 yr)   Grp 3: 400 mmol         Grp 3: 288 U/24 hr           & 40 mmol/L for Grp 3         
  *only 2 groups randomized*                                                         (per L of fluid infused)      
                                                                                                                   
  Lutterman et al. \[[@B17]\]   Retrospective           167 mmol                     High-dose insulin (mean       No difference in mean serum K
  *Diabetologia*1979            Adults (N = 24)         (standard)                   260 ± 60 U in 1st 6 hr)       No difference in K requirement over 12 hrs
                                                                                     vs. low dose 8 U/hr           
                                                                                                                   
  Lever et al. \[[@B18]\]       Retrospective           130-135 mmol                 IM or IV insulin              No difference in K requirement
  *Am J Med*1983                Adults (N = 73)         (standard)                   5-6 U/hr (for all)            6 hypokalemia (\< 3.3 mmol/L) in bicarb arm, 1 in control
                                                                                                                   
  Viallon et al. \[[@B20]\]     Retrospective           120 ± 40 mmol                IV insulin for all            More K requirement over 24 hr for bicarb arm,
  *Crit Care Med*1999           Adults (N = 39)         (mean)                       (dose unspecified)            *p*\< 0.001
                                                                                                                   1 hypokalemia (\< 3 mmol/L) in bicarb arm
                                                                                                                   
  Green et al. \[[@B24]\]       Retrospective           2.08 mmol/kg                 IV insulin for all            No difference in hypokalemia occurrence
  *Ann Emerg Med*1998           Pediatrics (N = 106)    (mean)                       (dose unspecified)            

Grp = group; IM = intramuscular; IV = intravenous; U = units; K = potassium; bicarb = bicarbonate; L = liter

A mixed adult and pediatric, three-arm prospective study, examined the association between mean cumulative bicarbonate doses and potassium requirement. The two groups that received saline and low-dose bicarbonate (mean 200 mmol) had comparable potassium supplementation during first 24 hours, whereas the third group with high bicarbonate dose (mean 400 mmol) received higher potassium supplementation \[[@B22]\].

### Tissue oxygenation

One adult RCT reported a significantly slower rate of decline in blood lactate and lactate to pyruvate ratio in the bicarbonate treatment arm, compared with saline control, in the first hour of treatment in DKA \[[@B13]\]. A slow decline in blood lactate to pyruvate ratio was used to imply tissue hypoxia. A subsequent pediatric nonrandomized prospective study demonstrated that the initial decline of in vivo P~50~(partial pressure of oxygen required to saturate 50% of the hemoglobin oxygen binding sites in a sample of whole blood) with DKA treatment was similar in both bicarbonate-treated group and controls. Bicarbonate therapy was not shown to affect oxygen transport adversely \[[@B16]\].

### Cerebrospinal fluid acidosis

One adult RCT performed CSF analysis in approximately half of the adult patient cohort to investigate the concern of paradoxical CSF acidosis with bicarbonate administration. The study did not find any statistically significant difference in CSF pH and bicarbonate levels within 24 hours in the bicarbonate-treatment group and control. However, patient numbers were small, and a trend for larger decline in CSF pH at 6 to 8 hours was observed in the bicarbonate group \[[@B14]\]. In another nonrandomized study, the study subjects who received additional bicarbonate therapy for DKA \[[@B23]\] were compared with controls from an older study, which used the usual treatment with insulin and saline \[[@B39]\]. Both therapies induced a paradoxical drop in CSF pH after treatment for DKA, which was accompanied by a significantly higher CSF P~CO2~and lesser increment in CSF bicarbonate level compared to blood, with no significant difference.

Secondary outcomes (clinical)
-----------------------------

### Neurological deterioration and cerebral edema

The possible association of bicarbonate therapy with the development of CE in DKA was highlighted in three nonrandomized studies that investigated risk factors for CE in pediatric DKA patients (Table [6](#T6){ref-type="table"}). Glaser et al. performed a multicenter, case-control study and identified 61 children with CE. Bicarbonate therapy was the only treatment variable associated with a greater risk of CE, after comparing with matched controls. The relative risk was 4.2 (95% confidence interval 1.5-12.1). Comparable proportions of children in the CE group and matched control had bicarbonate infused within 2 hours before neurological deterioration; hence no bias was detected \[[@B25]\]. Two other smaller studies found a trend for bicarbonate use and an association with CE, but the risk was not significant after adjusting for covariates, including baseline acidosis \[[@B26],[@B27]\]. A fourth pediatric study demonstrated that impaired conscious level in DKA was associated with younger age and lower initial pH, and CE cases had lower pH compared with matched controls with no CE, at every conscious level studied \[[@B28]\]. No studies have examined CE risks in adult DKA population, in which CE has only been rarely reported \[[@B40]-[@B42]\].

###### 

Studies on risk of cerebral edema in pediatric DKA population

  References                   Trial design      Case (children with CE)                               Control(s)                                              Associated risks of CE                                 Bicarb therapy and CE risk
  ---------------------------- ----------------- ----------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------
  Glaser et al. \[[@B25]\]     Retrospective     N = 61                                                N = 174 (*matched*)                                     Higher urea nitrogen and lower arterial P~CO2~levels   Bicarb therapy significantly a/w CE (matched control)
  *NEJM*2001                   case-control      Mean age: 8.9 yr                                      Mean age: 9.0 yr                                        at presentation (matched and random controls)          (23 of 61 with CE received bicarb;
                               (multicenter)     Mean pH: 7.06                                         Mean pH: 7.09                                           and                                                    vs. 43 of 174 matched controls);
                               USA + Australia   (*matched for age, DM onset, pH/bicarb, glucose*)     smaller increase in Na+ (matched control)               RR 4.2 (*p*= 0.008)                                    
                                                                                                       N = 181 (*random*)                                      and                                                    
                                                                                                       Mean age: 11.3 yr                                       Younger age, newly dx DM, lower pH, higher             
                                                                                                       Mean pH: 7.12                                           glucose & Cr at presentation (random control)          
                                                                                                                                                                                                                      
  Lawrence et al. \[[@B26]\]   Prospective +     N = 21                                                N = 42 (*mostlyrandom*)                                 Lower bicarb, higher urea, higher glucose levels       Trend towards association for bicarb therapy with CE
  *J Pediatrics*2005           Retrospective     Mean age: 9.0 yr                                      Mean age: 9.6 yr                                        at presentation                                        (data for bicarb therapy available in 17 CE cases,
                               case-control      Mean pH: 7.10                                         Mean pH: 7.20                                                                                                  with 34 random controls)
                               (multicenter)     (*13 prospective*,                                    (*matched for institution*                                                                                     
                               Canada            *8 retrospective*)                                    *and data collection duration*)                                                                                
                                                                                                                                                                                                                      
  Edge et al. \[[@B27]\]       Prospective       N = 43                                                N = 169                                                 Lower pH and/or lower bicarb levels, higher urea       Unadjusted OR of bicarb Rx for CE risk of 3.7 (*p*\< 0.05)
  *Diabetologia*2006           case-control      Mean age: 8.5 yr                                      Mean age: 8.9 yr                                        and potassium levels at presentation;                  After adjustments for matching variables and baseline
                               (multicenter)     Mean pH: 7.00                                         Mean pH: 7.20                                           more cumulative fluid volume given in 1st 4 hr,        acidosis, OR reduced to 1.5 (not significant)
                               United Kingdom    (*matched for age, sex, DM onset, admission month*)   insulin administration in 1st hr, and higher quantity                                                          
                                                                                                                                                               of insulin given over 1st 2 hr                         

DM = diabetes mellitus; bicarb = bicarbonate; Na+ = sodium; Cr = creatinine; CE = cerebral edema; neuro = neurological; RR = relative risk; OR = odds ratio; Rx = treatment

Other neurological outcomes
---------------------------

Three adult studies have examined neurological recovery as a secondary outcome. One RCT examined mental status at 0, 2, 6, 12, and 24 hours after therapy, and found no difference in both treatment arms \[[@B15]\]. Two other retrospective studies also found no difference in neurological status with bicarbonate therapy, in patients with varying degrees of impaired mental status at baseline \[[@B18],[@B20]\]. There were no pediatric studies on neurological recovery.

Hemodynamic outcome
-------------------

Three studies, including one RCT involving adult DKA patients with admission pH \> 6.90, reported changes in clinical parameters, such as heart rate, respiratory rate, and mean arterial pressure as outcome measures. None reported any difference in clinical parameters with or without added use of bicarbonate \[[@B15],[@B18],[@B20]\].

Discussion
==========

Summary of evidence
-------------------

We conducted a systematic review of the literature, comparing additional use of bicarbonate infusion versus the usual treatment with insulin and hydration, in pediatric and adult patients with DKA. We have found marked heterogeneity and no clear evidence, with regards to the threshold for, concentration, amount, and timing of bicarbonate administration. In addition to such variability of treatment, there was retrospective evidence of clinical harm, such as increased risk for CE and prolonged hospitalization in children, and weak evidence of physiological harm, such as transient paradoxical worsening of ketosis and increased need for potassium supplementation. Theoretical benefits perceived with rapid acidemia reversal were not evident, apart from weak evidence of transient improvement in acidosis, with no evidence of any clinical efficacy.

Physiological impact of bicarbonate therapy in DKA
--------------------------------------------------

The primary cause of acidemia in patients with DKA is ketoacidosis, with contribution from lactic acidosis and renal dysfunction. After metabolism of ketones during the recovery phase, bicarbonate is regenerated and aids the resolution of acidosis but is potentially affected by the development of hyperchloremia, which has been reported in more than 50% of adult and pediatric patients after 4 hours of therapy in DKA, and in more than 90% of patients by 8 to 20 hours \[[@B7],[@B43]\]. It was observed and suggested in these studies that hyperchloremic acidosis is likely contributed by preferential renal excretion of ketones over chloride anion and volume repletion with saline, with the most rapid rise in hyperchloremia coinciding with the period of greatest saline administration \[[@B43]\]. Theoretically, adjunct use of bicarbonate administration may be more beneficial in the scenario of reduced renal bicarbonate genesis with concomitant acute kidney injury or in hyperchloremic acidosis where there is deficiency of bicarbonate relative to chloride.

Although bicarbonate therapy in DKA has been shown in two RCTs to improve acidosis resolution in the initial few hours of therapy, the comparator consisted of sodium chloride infusion. Thus, the initial favorable physiologic outcome with bicarbonate therapy might represent a reduced risk of hyperchloremic acidosis. Despite so, patient numbers were small, and this transient physiological benefit had not been demonstrated to persist beyond the initial 2 hours. Concerns were raised that bicarbonate therapy might interfere with tissue oxidation and with the clearance or renal excretion of ketones, hence accounting for the paradoxical worsening of ketosis.

Severe acidosis may inhibit the action of insulin on glucose utilization. Insulin resistance in humans has been shown to be higher at lower pH range and resistance to fall steeply at pH above 7.2 \[[@B44]\]. Early and rapid correction of acidemia can theoretically increase insulin sensitivity. However, as discussed, there is no evidence of the above-postulated benefit of bicarbonate therapy. Instead, lower serum potassium and increased need for potassium supplementation had been demonstrated by mainly adult studies, including one small RCT, in the bicarbonate treatment arm. Although no fatal outcomes or arrhythmias had been reported as a result of hypokalemia, it would be prudent to pay close attention to this anticipated complication.

Acute reversal of acidemia with bicarbonate also has been linked to worsening of tissue hypoxia. Acidosis induces a mild increase in P~50~and reduced hemoglobin-oxygen affinity (Bohr effect), but at the same time is associated with lower levels of 2,3-diphosphoglycerate (2,3-DPG) in erythrocytes \[[@B45]\], which leads to a counteractive increased hemoglobin-oxygen affinity. In the initial presentation of DKA, a fine balance exists in favor of the former (Bohr effect) \[[@B16]\], which can theoretically be disrupted by rapid treatment of acidemia, as 2,3-DPG levels were demonstrated to remain strikingly low for days despite improvement in acidosis \[[@B46]\], resulting in net increase in hemoglobin-oxygen affinity and impaired tissue oxygenation. However, this phenomenon is generally seen in the initial treatment phase of DKA, regardless of bicarbonate therapy. P~50~, along with blood lactate to pyruvate ratio, are merely surrogate markers of peripheral tissue oxygenation used in studies. Therefore, there remains to be insufficient evidence that additional bicarbonate administration affects tissue oxygenation adversely.

Bicarbonate therapy in patients with DKA appeared to be associated with increased obtundation and profound cerebrospinal fluid (CSF) acidosis in an early study \[[@B47]\]. A possible explanation for this observation may be the preferential movement across the blood-brain barrier of CO~2~compared with bicarbonate during treatment of DKA, when both P~CO2~and bicarbonate levels rise in the blood. It was postulated that rapid reversal of acidemia with bicarbonate might promote paradoxical CSF acidosis and contribute to adverse neurological outcomes. However, we have not found any evidence that bicarbonate infusion causes increased paradoxical CSF acidosis compared with conventional DKA treatment.

In essence, most of the theoretical biochemical gains and harm with bicarbonate administration were not evident in actual case scenarios, and the overall physiological impact with such treatment is dismal.

Clinical impact of bicarbonate therapy in DKA
---------------------------------------------

CE followed by coma is a devastating complication of DKA, with an incidence of 1% and mortality of 24% \[[@B25],[@B27]\], and appears to be essentially exclusive to children and young adolescents \[[@B48]\]. The pathophysiology of CE remains unclear, and a detailed discussion on this is beyond the scope of this article. In essence, possible mechanisms include initial cerebral vasoconstriction and reduced cerebral blood flow from acidosis and hypocapnia, cytotoxic edema, and cerebral injury, followed by cerebral hyperemia, reperfusion injury, and vasogenic edema, coupled with increased blood brain barrier permeability, during the rehydration phase of DKA \[[@B48],[@B49]\]. Several reports of sudden death following irreversible coma in children and young adults with DKA were published in the 1960s, including development of diabetes insipidus in some, with postmortem findings of CE and neuronal degeneration \[[@B50]-[@B52]\].

From our earlier discussion, it is apparent that cerebral function in DKA is related to severity of acidosis, even when there is no occurrence of CE. There were no details on the reasons for bicarbonate administration in previously mentioned studies on CE in children with DKA, and it would be logical to assume that those who were given bicarbonate were likely to have more severe DKA or even circulatory collapse, factors which by themselves might predispose to adverse neurological outcomes. It should be noted that studies on risk factors for CE were based on historical cases, when the use of bicarbonate frequently accompanied high-dose insulin protocols, where the combination of both might have theoretically worsened the risk of CE.

Apart from the risk of CE, we also have discussed the retrospective evidence that bicarbonate therapy is associated with prolonged hospitalization in the pediatric DKA cohort. Such studies were again subjected to the natural confounder that children admitted with a lower arterial pH (who were potentially more ill) and in earlier study years were more likely to be given sodium bicarbonate. On the other hand, there is no evidence that the rapid reversal of acidemia with bicarbonate therapy improves any clinical outcome, especially in the pediatric cohort. Documentation of improved mental status from initial diabetic coma following treatment (including bicarbonate therapy) came only from pediatric and adult case reports and series \[[@B23],[@B29],[@B30],[@B36]\]. It could not be ascertained, however, if a favorable neurological outcome was attributable to the use of initial bicarbonate therapy.

In addition, there is no evidence of improved hemodynamic stability with the use of bicarbonate administration in DKA. Much of the perceived benefit in acute reversal of severe acidemia is only based on animal and experimental studies, which demonstrated weakened end-organ response to catecholamines at pH \< 7.2, with bradycardia, negative inotropism, impaired cardiac output, peripheral vasodilatation, and refractory hypotension \[[@B53]\]. Therefore, even though the clinical harm with bicarbonate treatment is merely an association (and not causation), the lack of clinical benefits does not justify its routine use especially in children.

Limitations of studies
----------------------

In general, patient numbers in the three adult RCTs were small and lacked the statistical power to examine clinical outcomes. Most prospective trials excluded patients with severe concomitant illnesses, in whom the adverse cardiovascular effects of severe acidemia are believed to be more significantly seen. There were no trials performed in the scenario of more severe acidemia (pH \< 6.85), and it seems unlikely that such studies will be performed. Understandably, documentation of presumed benefits of bicarbonate rescue in cases of DKA presenting with more severe acidemia and cardiovascular collapse or significant hemodynamic compromise were confined to case reports \[[@B32],[@B35],[@B36]\]. Clinical judgment, opinion, and expertise prevail in such circumstances in the absence of trials. There are a paucity of data on bicarbonate administration in the pediatric DKA population with no randomized trials performed, forcing the extrapolation of adult data, despite the likelihood that the pathophysiology in both cohorts are fundamentally different. Studies that report clinical harm with bicarbonate treatment in children are all retrospective in design and subjected to the various confounders as discussed earlier.

There were limited DKA trials during the past decade, especially in the context of modern day emergency medicine or intensive care. The data of the past decade were mostly focused on the adverse neurological outcome of bicarbonate treatment in the pediatric DKA population. There is increasing recognition of the development of hyperchloremic acidosis for the treatment phase of DKA with fluid resuscitation, which might impact the resolution of acidemia \[[@B54]\]. The clinical effects of hyperchloremic acidosis remain uncertain.

Conclusions
===========

The evidence to date does not support the use of bicarbonate administration for the emergent treatment of DKA, especially in the pediatric population, in view of possible clinical and physiological harm and the lack of clinical or sustained physiological benefits. There also is insufficient evidence to justify the recommendation of bicarbonate administration in more extreme acidemia of pH \< 6.90. Future research should focus on the use of more balanced and physiological resuscitation fluids with buffering capacity, in the modern context of DKA management, with the goal of reducing the component of hyperchloremic acidosis in DKA while minimizing the risk of CSF acidosis and associated CE.
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